Modality
Gene Editing
MOA
GLP-1/GIP
Target
JAK1
Pathway
Epigenetic
ET
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
Feb 2022
→ Jan 2025
NDA/BLACurrent
NCT05139104
1,973 pts·ET
2022-02→2025-01·Terminated
1,973 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-271.2y agoPh3 Readout· ET
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-01-27 · 1.2y ago
ET
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05139104 | NDA/BLA | ET | Terminated | 1973 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| MLY-3531 | Mineralys | NDA/BLA | JAK1 |